Navigation Links
Epigenetic control of cardiogenesis

This press release is available in German.

Many different tissues and organs form from pluripotent stem cells during embryonic development. To date it had been known that these processes are controlled by transcription factors for specific tissues. Scientists from the Max Planck Institute for Molecular Genetics in Berlin, in collaboration with colleagues at MIT and the Broad Institute in Boston, have now been able to demonstrate that RNA molecules, which do not act as templates for protein synthesis, participate in these processes as well. The scientists knocked down a gene for long non-coding RNA molecules (lncRNA) and thereby disrupted the development of the heart to an extent that was lethal to the embryos. Genesis of the ventral body wall was also impaired. It became apparent that the lncRNA participates in controlling transcription factors that themselves are responsible for controlling tissue- and organogenesis. The lncRNA itself thus acts as a modulating factor in these processes.

RNA molecules more than 300 nucleotides long and not exhibiting any protein-coding read frames are denoted as long non-coding RNA. They are known to interact with histone-modifying protein complexes that control the activation state of genes (activatable, active, or repressed), as well as influencing the level of their activity. This occurs, for example, through the transfer of methyl groups to histones, the DNA-packaging proteins. Modifications to the histones such as these can be copied during cell division and thus promulgate the activation state of genes from cell to cell across several stages of differentiation.

Max Planck scientists led by Bernhard Herrmann have proven for the first time that lncRNAs may also be indispensable for embryonic development. This was previously known primarily for transcription factors. They discovered an lncRNA, termed Fendrr, which is specifically formed in the progenitor cells of the heart and ventral body wall. After knocking down Fendrr in a mouse, the heart and ventral body wall were malformed, which was lethal to the embryos. The malformations first arose, however, several days after Fendrr had already been knocked down in the progenitor cells. In the case of transcription factors, the malformations appear, in contrast, after their inactivation for cells in which the gene is normally active.

This delay between the expression of the Fendrr-RNA and the appearance of the malformation can be explained by the specific effect of this new class of regulators. They influence the epigenetic control of target genes, including important transcription factors, namely by binding to histone-modifying protein complexes. Thus, they influence the fate of the descendants of cells in which they themselves were only briefly active.

The scientists now hope to locate further lncRNAs that control cardiogenesis and additional processes of embryonic development in mammals, and shed light on the mechanism of how they operate. Fendrr is probably only one of many lncRNAs that participate in epigenetic control of regulators for tissue- and organogenesis.


Contact: Bernhard G. Herrmann

Related medicine news :

1. Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
2. Epigenetics emerges powerfully as a clinical tool
3. New evidence for epigenetic effects of diet on healthy aging
4. Personal epigenetic signatures found consistent in prostate cancer patients metastases
5. Depo-Provera Birth Control Might Raise Breast Cancer Risk
6. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
7. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
8. How the brains daily clock controls mood: A new project
9. Guidelines say diet, exercise, weight control improve odds after cancer diagnosis
10. Control of gene expression: Histone occupancy in your genome
11. MSU plan would control deadly tsetse fly
Post Your Comments:
Related Image:
Epigenetic control of cardiogenesis
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: